此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Lecigon对晚期帕金森病患者有效性和安全性的长期观察研究 (ELEGANCE)

2026年10月1日 更新者:Britannia Pharmaceuticals Ltd.

ELEGANCE - 一项关于左旋多巴-恩他卡朋-卡比多巴肠凝胶 (Lecigon®) 在常规护理中晚期帕金森病患者长期有效性和安全性的非干预研究

This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).

Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.

In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.

研究概览

详细说明

Study design:

Non-interventional study, primary data collection.

No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.

The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.

The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.

Primary Objectives:

  • Long-term effectiveness of Lecigon®
  • Long-term safety of Lecigon®

Secondary Objectives:

  • Patient non-motor symptoms and quality of life
  • Healthcare resource utilisation by patients

研究类型

观察性的

注册 (实际的)

312

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Copenhagen、丹麦、2400
        • Bispebjerg Hospital
      • Sofia、保加利亚、1113
        • Sveti Naum
      • Osijek、克罗地亚、31000
        • UHC Osijek, J. Klinici za neurologiju
      • Rijeka、克罗地亚
        • University Hospital Centre Rijeka (KBC Rijeka)
      • Zagreb、克罗地亚、10000
        • University Hospital Centre (KBC Zagreb)
      • Zagreb、克罗地亚、10000
        • Klinička bolnica Dubrava
      • Budapest、匈牙利
        • Semmelweis Egyetem Neurológiai Klinika Budapest
      • Pécs、匈牙利、7623
        • Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
      • Szeged、匈牙利、6725
        • SZTE Szent-Györgyi Albert Klinikai Közpon
      • Graz、奥地利、8036
        • Universitätsklinik für Neurologie, Medizinische Universität Graz
      • Hermagor、奥地利、9620
        • Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
      • Innsbruck、奥地利、6020
        • Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
      • Linz、奥地利、4020
        • Kepler Universitätsklinikum
      • Bad Segeberg、德国、23795
        • Segeberger Kliniken GmbH Neurologisches Zentrum
      • Beelitz-Heilstätten、德国、14547
        • Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
      • Berlin、德国、10117
        • Charité - Universitätsmedizin Berlin
      • Cologne、德国
        • Uniklinik Köln
      • Coppenbrügge、德国、31863
        • Krankenhaus Lindenbrunn
      • Essen、德国、45147
        • Klinik für Neurologie - Universitätsklinikum Essen
      • Freiburg im Breisgau、德国、79106
        • Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
      • Göttingen、德国、37075
        • Zentrum für Seltene Erkrankungen Göttingen
      • Marburg、德国、35043
        • Universitätsklinikum Giessen und Marburg
      • Oldenburg、德国、26122
        • Evangelisches Krankenhaus Oldenburg
      • Osnabrück、德国、49076
        • Klinikum Osnabrück GmbH Klinik für Neurologie
      • Tübingen、德国、72076
        • Universitätsklinikum Tübingen
      • Ulm、德国、89081
        • RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
      • Wolfach、德国、77709
        • Parkinson-Klinik Ortenau
      • Brno、捷克语
        • Masaryk university
      • Olomouc、捷克语
        • Fakultní nemocnice Olomouc
      • Ljubljana、斯洛文尼亚、1000
        • Department of Neurology, University Medical Centre
      • Maribor、斯洛文尼亚、2000
        • Univerzitetni klinični center Maribor
      • Bruges、比利时、8000
        • AZ Sint-Jan
      • Edegem、比利时、2650
        • Antwerp University Hospital
      • Ghent、比利时
        • Ghent University Hospital
      • Liège、比利时
        • University Hospital Liege
      • Tournai、比利时、7500
        • Centre Hospitalier de Wallonie picarde (Chwapi)
      • Dublin、爱尔兰、D07 R2WY
        • The Dublin Neurological Institute, Mater Hospital
      • Dublin、爱尔兰、D04 T6F4
        • St. Vincent's University Hospital
      • Gothenburg、瑞典、413 45
        • Sahlgrenska University Hospital
      • Lund、瑞典
        • Skånes universitetssjukhus Lund
      • Uppsala、瑞典、751 85
        • Uppsala university hospital
      • Brasov、罗马尼亚、500326
        • Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
      • Bucharest、罗马尼亚、050098
        • Bucharest University Emergency Hospital
      • Bucharest、罗马尼亚
        • Fundeni Clinical Institute
      • Bucharest、罗马尼亚、011461
        • Spitalul Universitar de Urgență Elias
      • Bucharest、罗马尼亚、020125
        • Colentina Hospital Bucharest
      • Cluj-Napoca、罗马尼亚、400347
        • County Emergency Hospital Cluj-Napoca
      • Constanța、罗马尼亚、900591
        • County Clinical Emergency Hospital of Constanta
      • Timișoara、罗马尼亚、300723
        • Timiş County Emergency Clinical Hospital- Neurology 1
      • Timișoara、罗马尼亚、300723
        • Timiş County Emergency Clinical Hospital
      • Târgu Mureş、罗马尼亚、540136
        • Emergency County Hospital Targu Mures
      • Groningen、荷兰、97139713
        • University Medical Center Groningen
      • Barcelona、西班牙、08025
        • Hospital de la Santa Creu i Sant Pau
      • Madrid、西班牙、28040
        • Hospital Clínico San Carlos
      • Madrid、西班牙、28034
        • Hospital Universitario Ramón y Cajal
      • Madrid、西班牙
        • Hospital de la Princesa
      • Seville、西班牙、41013
        • Hospital Virgen del Rocio

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Treating physician's normal patient pool

描述

Inclusion Criteria:

  • Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
  • Patients or legal representative must have signed informed consent to participate in the study
  • Patients are not taking part in another clinical (interventional) study at the same time

Exclusion Criteria:

  • Patients with contraindications as defined in the current version of the SmPC for Lecigon®
  • Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
  • Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:OTHER

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications)

24 months
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living)

24 months
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses

24 months
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation

24 months
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected

24 months
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I)

24 months
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C)

24 months
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
大体时间:24 months

To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item.

24 months
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
大体时间:24 months

To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected

24 months

次要结果测量

结果测量
措施说明
大体时间
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS)

24 months
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2)

24 months
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living)

24 months
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39)

24 months
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit

24 months

其他结果措施

结果测量
措施说明
大体时间
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation

24 months
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation

24 months
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
大体时间:24 months

To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation

24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年7月6日

初级完成 (估计的)

2026年10月7日

研究完成 (估计的)

2026年10月7日

研究注册日期

首次提交

2021年7月29日

首先提交符合 QC 标准的

2021年9月3日

首次发布 (实际的)

2021年9月14日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅